SCA
NVAX icon

SAC Capital Advisors’s Novavax NVAX Stock Holding History

SAC Capital Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,610
Closed -$871K – 697
2014
Q1 		$871K Buy
+9,610
New +$1.07M ﹤0.01% 990
2013
Q4 		– Sell
-670
Closed -$42K – 1909
2013
Q3 		$42K Buy
+670
New +$37.7K ﹤0.01% 1727

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAC Capital Advisors's NVAX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Novavax (NVAX) in Q2 2014, closing a stake of 9,610 shares — an estimated $871K sold.

SAC Capital Advisors first reported a position in NVAX in Q3 2013 and held it in 2 quarters. The position peaked at $871K in Q1 2014. 137 funds tracked by Wall St. Rank hold NVAX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Novavax position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 9,610 Novavax shares in Q2 2014, an estimated $871K.
  • SAC Capital Advisors first reported a position in Novavax in Q3 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Novavax position peaked at $871K in Q1 2014.
  • 137 funds tracked by Wall St. Rank held Novavax as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.